The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Estimating benefit from dose dense adjuvant chemotherapy for early breast cancer in the PANTHER randomized phase 3 trial.
 
Alexios Matikas
Honoraria - Veracyte
Speakers' Bureau - Roche; Seagen (Inst)
Research Funding - AstraZeneca (Inst); MSD (Inst); Novartis (Inst); Veracyte (Inst)
 
Michael Gnant
Employment - Sandoz (I)
Honoraria - Amgen; AstraZeneca; Daiichi Sankyo Europe GmbH; EPG Health; Lilly; Menarini; MSD; Novartis; Pierre Fabre
Consulting or Advisory Role - AstraZeneca; Daiichi-Sankyo; Lilly; Menarini; MSD Oncology; Novartis; Veracyte
Expert Testimony - Lilly; Veracyte
Travel, Accommodations, Expenses - Lilly; Novartis
Other Relationship - ABCSG GmbH; ABCSG Research Services GmbH
 
Hemming Johansson
No Relationships to Disclose
 
Michael Untch
Honoraria - Agendia (Inst); Amgen (Inst); Art tempi (Inst); AstraZeneca; AstraZeneca (Inst); Baxter (Inst); Daiji Sankyo (Inst); Eisai Europe (Inst); Gilead Sciences (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche Pharma AG (Inst); Sanofi (Inst); Seagen (Inst)
Consulting or Advisory Role - Agendia (Inst); Amgen (Inst); Art tempi (Inst); AstraZeneca (Inst); Daiichi Sankyo Europe GmbH (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Medac (Inst); MSD Oncology (Inst); Myriad Genetics (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche Pharma AG (Inst); Sanofi Aventis GmbH (Inst); Stemline Therapeutics
 
Nikolaos Tsiknakis
No Relationships to Disclose
 
Richard Greil
Stock and Other Ownership Interests - Lilly (Inst); Novo Nordisk (Inst)
Honoraria - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Gilead Sciences; Merck; MSD; Novartis; Roche; Sandoz; Sanofi; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Gilead Sciences; Janssen; Merck; MSD; Novartis; Roche; Sanofi; Takeda
Research Funding - Abbvie; Abbvie; Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo Europe GmbH (Inst); Gilead Sciences (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Roche (Inst); Sandoz (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Gilead Sciences; Janssen-Cilag; MSD; Novartis; Roche
 
Sibylle Loibl
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); EirGenix (Inst); Eisai Europe (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Menarini Group (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Novartis (Inst); Olema Pharmaceuticals (Inst); Pfizer (Inst); Pierre Fabre (Inst); Relay Therapeutics (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst)
Speakers' Bureau - AstraZeneca (Inst); Daiichi Sankyo Europe GmbH (Inst); Gilead Sciences (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Seagen (Inst)
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); Menarini Group (Inst); MolecularHealth (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Digital Ki67 Evaluator, VM Scope GmbH (Inst); Patent Issued EP15702464.7 (Inst); Patent Pending EP14153692.0 (Inst); Patent Pending EP19808852.8 (Inst); Patent Pending EP21152186.9 (Inst)
 
Theodoros Foukakis
Honoraria - UpToDate
Consulting or Advisory Role - AstraZeneca (Inst); Gilead Sciences (Inst); Roche (Inst)
Research Funding - AstraZeneca (Inst); Novartis (Inst); Veracyte (Inst)
 
Jonas C. S. Bergh
Stock and Other Ownership Interests - Stratipath AB
Honoraria - AstraZeneca; Roche
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Merck (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst)
Other Relationship - UpToDate